CD38 CAR T-cells

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD38 CAR T-cells
Drug Alias Nameanti-CD38 CAR T-cell therapy (Zhejiang University/Yake Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Yake Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A